title: Opposite effects of endogenous nitric oxide and prostaglandin F2 alpha in the rat mesenteric bed.
abstract: 1. The relationship between the effects of endogenous nitric oxide (NO) and prostanoids on the noradrenaline (NA)-induced contractions and the mechanisms involved were investigated in the rat perfused mesenteric bed, using NG-nitro-L-arginine methyl ester (l-NAME), a NO synthase inhibitor and sodium nitroprusside (SNP), a NO donor. 2. The constrictor responses to NA were reduced to 50% by the cyclooxygenase inhibitor 10 microm indomethacin as well as by 1 microM SNP. When indomethacin and SNP were perfused simultaneously the contractions were further reduced. 3. The NA-induced contractions were increased by the addition of 400 microM L-NAME and the addition of either indomethacin or SNP abolished such increases. The simultaneous perfusion of both agents further reduced the contractions. 4. Removal of the endothelium increased NA-induced contractions to a similar extent as L-NAME and this increase was abolished by indomethacin as well as by SNP. 5. The perfusion of 10 microM NA augmented the release of prostaglandin (PG) F2 alpha by the mesenteric bed without modifications in any other prostanoid. In the presence of L-NAME, this effect was further increased. However, SNP abolished the NA-induced stimulation of PGF2 alpha release. 6. In de-endothelialized preparations NA also stimulated PGF2 alpha production as observed in intact preparations. This effect was more marked in the presence of L-NAME; in contrast, SNP abolished the stimulation. 7. In conclusion, the present results suggest an opposite action between NO and PGF2 alpha on the NA-induced contractions in the rat mesenteric bed.
authors.affiliation: Instituto de Investigaciones Farmacológicas, CONICET, Junín 956-number 5 piso, 1113 Buenos Aires, Argentina.
authors.forename: H A
authors.initials: HA
authors.lastname: Peredo
mesh_terms: D000818:Animals; D015237:Dinoprost / Q000502:physiology*; D004730:Endothelium, Vascular / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000502:physiology*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D052250:Nitric Oxide Synthase Type III; D009599:Nitroprusside / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D011453:Prostaglandins / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013152:Splanchnic Circulation / Q000187:drug effects / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D020030:Nitric Oxide Donors; D011453:Prostaglandins; D014662:Vasoconstrictor Agents; D009599:Nitroprusside; D009569:Nitric Oxide; D015237:Dinoprost; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; C496316:Nos3 protein, rat; D019331:NG-Nitroarginine Methyl Ester; D009638:Norepinephrine